[Results of radiotherapy with cobalt-60 in tonsillar neoplasms].
From 1963 to 1978 119 patients with a carcinoma of the tonsillar fossa received cobalt-60-therapy from 60 to 70 Gy to the primary lesion and the lymph nodes. The 5-year-survival-rate was 34%, with a combined therapy of surgery and irradiation it was 43.6%. For 44 patients with a sarcoma of the tonsillar fossa the 5-year-survival was 32%. For the patients with a carcinoma chemotherapy was only given for palliation.
D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D003037:Cobalt Radioisotopes / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000532:radiotherapy*; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014067:Tonsillar Neoplasms / Q000532:radiotherapy*
D003037:Cobalt Radioisotopes
Ergebnisse der Strahlentherapie mit Kobalt-60 bei Tonsillenmalignomen.